PDCD1 and neoplasm: Using the CDK4/6 inhibitor palbociclib and PD-1 immunotherapy in a mouse colon cancer model resulted in significant tumor shrinkage and extended survival, highlighting a new regulatory mechanism involving cyclin kinase and ubiquitin ligase for PD-L1 [35].